{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:03:02Z","timestamp":1762642982926,"version":"build-2065373602"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972838","82102805","82200019","82272722"],"award-info":[{"award-number":["81972838","82102805","82200019","82272722"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["2023ZZTS0843"],"award-info":[{"award-number":["2023ZZTS0843"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.critrevonc.2023.104223","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T23:02:04Z","timestamp":1701212524000},"page":"104223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Somatostatin receptor2 (SSTR2) expression, prognostic implications, modifications and potential therapeutic strategies associates with head and neck squamous cell carcinomas"],"prefix":"10.1016","volume":"193","author":[{"given":"Songqing","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiadi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjing","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Xu.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2023.104223_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1084713","article-title":"Transcriptomic profiling revealed FZD10 as a novel biomarker for nasopharyngeal carcinoma recurrence","volume":"12","author":"Tulalamba","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib2","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib3","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study","volume":"41","author":"Harrington","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104223_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2023.104223_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2478\/bjmg-2021-0005","article-title":"Simultaneously both expression of LMP-1 and methylation of E-cadherin: Molecular biomarker in stage IV of nasopharyngeal carcinoma patients","volume":"24","author":"Lao","year":"2021","journal-title":"Balk. J. Med. Genet."},{"key":"10.1016\/j.critrevonc.2023.104223_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-021-00834-3","article-title":"Drug Development in Neuroendocrine Tumors: What Is on the Horizon?","volume":"22","author":"Garcia-Alvarez","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-31823-1","article-title":"Molecular simulations of SSTR2 dynamics and interaction with ligands","volume":"13","author":"Gervasoni","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2023.104223_bib9","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1021\/acs.jmedchem.8b02036","article-title":"Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo","volume":"62","author":"White","year":"2019","journal-title":"J. Med Chem."},{"key":"10.1016\/j.critrevonc.2023.104223_bib10","first-page":"11","article-title":"Cloning and characterization of novel testis-Specific diacylglycerol kinase \u03b7 splice variants 3 and 4","author":"Murakami","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2023.104223_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin receptors: From signaling to clinical practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front Neuroendocr."},{"key":"10.1016\/j.critrevonc.2023.104223_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20308-8","article-title":"Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy","volume":"12","author":"Lechner","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2023.104223_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194944","article-title":"Sstr2 in nasopharyngeal carcinoma: Relationship with latent ebv infection and potential as a therapeutic target","volume":"13","author":"Emanuel","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2023.104223_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2017.07.082","article-title":"DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer","volume":"630","author":"Li","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.critrevonc.2023.104223_bib15","article-title":"Relationship between somatostatin receptor subtype expression and clinicopathology","author":"Qiu","year":"2006","journal-title":"Ki-67, Bcl-2 p53 Colorectal Cancer"},{"key":"10.1016\/j.critrevonc.2023.104223_bib16","unstructured":"Klomp M.J., Dalm S.U., De Jong & M, et al. Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer. doi: 10.1007\/s11154\u2013020-09607-z\/Published."},{"key":"10.1016\/j.critrevonc.2023.104223_bib17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41417-020-0196-5","article-title":"Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy","volume":"28","author":"Si","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.critrevonc.2023.104223_bib18","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/ijc.31771","article-title":"Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer","volume":"144","author":"Lehman","year":"2019","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104223_bib19","unstructured":"He J.-H., Wang J., Yang Y.-Z., et al. Original Article SSTR2 is a prognostic factor and a promising therapeutic target in glioma. 2021. https:\/\/www.string-db.org\/."},{"key":"10.1016\/j.critrevonc.2023.104223_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2021.09.046","article-title":"Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma","volume":"162","author":"Lechner","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104223_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.823667","article-title":"Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors","volume":"12","author":"Roden","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib22","article-title":"SSTR2 positively associates with EGFR and predicts poor prognosis in nasopharyngeal carcinoma","author":"Xu","year":"2023","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/s13000-016-0461-y","article-title":"SSTR2 promoter hypermethylation is associated with the risk and progression of laryngeal squamous cell carcinoma in males","volume":"11","author":"Shen","year":"2016","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib24","doi-asserted-by":"crossref","unstructured":"Stafford N., Condon \u00c3.L., Mjc Rogers \u00c3., et al. The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions, 2003.","DOI":"10.1046\/j.1365-2273.2003.00711.x"},{"key":"10.1016\/j.critrevonc.2023.104223_bib25","doi-asserted-by":"crossref","DOI":"10.1007\/s00405-007-0539-y","article-title":"The expression of somatostatin receptors 3, 4 and 5 in laryngeal pathology","author":"Condon","year":"2008","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194828","article-title":"Molecular and clinical implications of somatostatin receptor profile and somatostatin analogues treatment in oral cavity squamous cell carcinoma","volume":"13","author":"Sanjuan\u2010sanjuan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2023.104223_bib27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/annonc\/mdf142","article-title":"The clinical role of somatostatin analogues as antineoplastic agents: Much ado about nothing?","volume":"13","author":"Hejna","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib28","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/jclinpath-2020-206903","article-title":"SSTR2a is constantly expressed in lymphoepithelioma-like carcinoma with squamous differentiation other than that with glandular differentiation","volume":"74","author":"Tao","year":"2021","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib29","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00259-021-05587-7","article-title":"Somatostatin receptor imaging with [68Ga]Ga-DOTATATE positron emission tomography\/computed tomography (PET\/CT) in patients with nasopharyngeal carcinoma","volume":"49","author":"Zhao","year":"2022","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2023.104223_bib30","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1292\/jvms.15-0002","article-title":"Alteration of somatostatin receptor 2 expression in canine mammary gland tumor","volume":"77","author":"Sakai","year":"2015","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.critrevonc.2023.104223_bib31","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12094-015-1406-8","article-title":"The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma","volume":"18","author":"Jia","year":"2016","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3727\/096504021X16135618512563","article-title":"(\u2212)-Epigallocatechin-3-Gallate Inhibits EBV Lytic Replication via Targeting LMP1-Mediated MAPK Signal Axes","volume":"28","author":"Li","year":"2020","journal-title":"Oncol. Res"},{"key":"10.1016\/j.critrevonc.2023.104223_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110649","article-title":"Anti-EGFR therapies in nasopharyngeal carcinoma","volume":"131","author":"Chen","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2023.104223_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.05.018","article-title":"Pathogenic role of Epstein-Barr virus latent membrane protein-1 in the development of nasopharyngeal carcinoma","volume":"337","author":"Yoshizaki","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2023.104223_bib35","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1128\/JVI.01703-10","article-title":"Epstein-Barr Virus LMP1 Activates EGFR, STAT3, and ERK through Effects on PKC\u03b4","volume":"85","author":"Kung","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib36","series-title":"Advances in Experimental Medicine and Biology","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-319-24738-0_3","article-title":"Epigenetic alterations in epstein-barr virus-associated diseases","author":"Niller","year":"2016"},{"key":"10.1016\/j.critrevonc.2023.104223_bib37","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2015.60.7846","article-title":"Nasopharyngeal cancer: Molecular landscape","volume":"33","author":"Bruce","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.humpath.2021.08.004","article-title":"Somatostatin receptor 2 is highly sensitive and specific for Epstein-Barr virus\u2013associated nasopharyngeal carcinoma","volume":"117","author":"Viswanathan","year":"2021","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib39","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/j.1582-4934.2010.01125.x","article-title":"Somatostatin receptor biology in neuroendocrine and pituitary tumours: Part 1 - molecular pathways","volume":"14","author":"Cakir","year":"2010","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.critrevonc.2023.104223_bib40","article-title":"Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib41","doi-asserted-by":"crossref","first-page":"39356","DOI":"10.1074\/jbc.M304524200","article-title":"sst2 somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation","volume":"278","author":"Lahlou","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2023.104223_bib42","doi-asserted-by":"crossref","unstructured":"Patel Y.C. Somatostatin and Its Receptor Family. 1999. http:\/\/www.idealibrary.com.","DOI":"10.1006\/frne.1999.0183"},{"key":"10.1016\/j.critrevonc.2023.104223_bib43","first-page":"379","article-title":"Somatostatin analogues inhibit cancer cell proliferation in an SSTR2-dependent manner via both cytostatic and cytotoxic pathways","volume":"21","author":"Zou","year":"2009","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2023.104223_bib44","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1210\/en.2005-0001","article-title":"Src homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma","volume":"146","author":"Zatelli","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.critrevonc.2023.104223_bib45","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1091\/mbc.e03-02-0069","article-title":"Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation","volume":"14","author":"Ferjoux","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.critrevonc.2023.104223_bib46","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1523\/JNEUROSCI.3834-04.2004","article-title":"Somatostatin receptor 2 is activated in cortical neurons and contributes to neurodegeneration after focal ischemia","volume":"24","author":"Stumm","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.critrevonc.2023.104223_bib47","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrg3230","article-title":"Functions of DNA methylation: Islands, start sites, gene bodies and beyond","volume":"13","author":"Jones","year":"2012","journal-title":"Nat. Rev. Genet"},{"key":"10.1016\/j.critrevonc.2023.104223_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194905","article-title":"Comparing the effect of multiple histone deacetylase inhibitors on sstr2 expression and [111in]in\u2010dotatate uptake in net cells","volume":"13","author":"Klomp","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2023.104223_bib49","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2967\/jnumed.121.262928","article-title":"Heterogeneity of SSTR2 Expression Assessed by 68Ga-DOTATOC PET\/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors","volume":"63","author":"Fonti","year":"2022","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.critrevonc.2023.104223_bib50","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1210\/en.2007-1525","article-title":"Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications","volume":"149","author":"Torrisani","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.critrevonc.2023.104223_bib51","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","article-title":"Navigating the DNA methylation landscape of cancer","volume":"37","author":"Nishiyama","year":"2021","journal-title":"Trends Genet."},{"key":"10.1016\/j.critrevonc.2023.104223_bib52","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1158\/1535-7163.MCT-15-0260","article-title":"Genome-wide identification of a methylation gene panel as a prognostic biomarker in nasopharyngeal carcinoma","volume":"14","author":"Jiang","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2023.104223_bib53","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-013-0654-0","article-title":"DNA methylation in tumour and normal mucosal tissue of head and neck squamous cell carcinoma (HNSCC) patients: New diagnostic approaches and treatment","volume":"30","author":"Laytragoon-Lewin","year":"2013","journal-title":"Med. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103399","article-title":"DNA methylation in oral squamous cell carcinoma: from its role in carcinogenesis to potential inhibitor drugs","volume":"164","author":"Flausino","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225630","article-title":"Head and neck cancers are not alike when tarred with the same brush: An epigenetic perspective from the cancerization field to prognosis","volume":"13","author":"Camuzi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2023.104223_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-018-0202-2","article-title":"Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer","volume":"51","author":"Byeon","year":"2019","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.critrevonc.2023.104223_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib58","series-title":"Advances in Cancer Research","first-page":"161","article-title":"EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells","author":"Talukdar","year":"2020"},{"key":"10.1016\/j.critrevonc.2023.104223_bib59","doi-asserted-by":"crossref","first-page":"14481","DOI":"10.1002\/anie.202003500","article-title":"Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations","volume":"59","author":"Jang","year":"2020","journal-title":"Angew. Chem. - Int. Ed."},{"key":"10.1016\/j.critrevonc.2023.104223_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112758","article-title":"Chemotherapy and chemo-resistance in nasopharyngeal carcinoma","volume":"207","author":"Guan","year":"2020","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.critrevonc.2023.104223_bib61","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/MNM.0b013e328364eaab","article-title":"Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET\/CT imaging in well-differentiated thyroid cancer","volume":"34","author":"Ocak","year":"2013","journal-title":"Nucl. Med Commun."},{"key":"10.1016\/j.critrevonc.2023.104223_bib62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00259-014-2905-5","article-title":"68Ga-DOTA0-Tyr3-octreotide positron emission tomography in nasopharyngeal carcinoma","volume":"42","author":"Schartinger","year":"2015","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2023.104223_bib63","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00259-013-2442-7","article-title":"68Ga-DOTA0-Tyr3-octreotide positron emission tomography in head and neck squamous cell carcinoma","volume":"40","author":"Schartinger","year":"2013","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2023.104223_bib64","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00259-021-05587-7","article-title":"Somatostatin receptor imaging with [68Ga]Ga-DOTATATE positron emission tomography\/computed tomography (PET\/CT) in patients with nasopharyngeal carcinoma","volume":"49","author":"Zhao","year":"2022","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2023.104223_bib65","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00259-011-2003-x","article-title":"Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET\/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy","volume":"39","author":"Sainz-Esteban","year":"2012","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2023.104223_bib66","doi-asserted-by":"crossref","unstructured":"Lococo F., Perotti G., Cardillo G., et al. Multicenter Comparison of 18 F-FDG and 68 Ga-DOTA-Peptide PET\/CT for Pulmonary Carcinoid. 2015. www.nuclearmed.com.","DOI":"10.1097\/RLU.0000000000000641"},{"key":"10.1016\/j.critrevonc.2023.104223_bib67","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2023.104223_bib68","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jconrel.2014.03.054","article-title":"Controlled drug delivery systems: Past forward and future back","volume":"190","author":"Park","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2023.104223_bib69","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/psc.2481","article-title":"Octreotide labeled aggregates containing platinum complexes as nanovectors for drug delivery","volume":"19","author":"Accardo","year":"2013","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.critrevonc.2023.104223_bib70","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1080\/10717544.2018.1516003","article-title":"Identification and imaging of miR-155 in the early screening of lung cancer by targeted delivery of octreotide-conjugated chitosan-molecular beacon nanoparticles","volume":"25","author":"Zhu","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.critrevonc.2023.104223_bib71","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejca.2022.09.009","article-title":"Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy","volume":"176","author":"Evans","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104223_bib72","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-020-02938-1","article-title":"Fluorescent Nanoparticles Coated with a Somatostatin Analogue Target Blood Monocyte for Efficient Leukaemia Treatment","volume":"37","author":"Abdellatif","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.critrevonc.2023.104223_bib73","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2021.12.030","article-title":"Evolution of drug delivery systems: From 1950 to 2020 and beyond","volume":"342","author":"Park","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2023.104223_bib74","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.actbio.2016.04.025","article-title":"Improved hemocompatibility of silicone rubber extracorporeal tubing via solvent swelling-impregnation of S-nitroso-N-acetylpenicillamine (SNAP) and evaluation in rabbit thrombogenicity model","volume":"37","author":"Brisbois","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.critrevonc.2023.104223_bib75","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1016\/j.bmc.2018.06.032","article-title":"New somatostatin-drug conjugates for effective targeting pancreatic cancer","volume":"26","author":"Ragozin","year":"2018","journal-title":"Bioorg. Med Chem."},{"key":"10.1016\/j.critrevonc.2023.104223_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11050220","article-title":"Octreotide conjugates for tumor targeting and imaging","volume":"11","author":"Figueras","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2023.104223_bib77","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ijbiomac.2022.03.057","article-title":"A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors","volume":"207","author":"Aghanejad","year":"2022","journal-title":"Int J. Biol. Macromol."},{"key":"10.1016\/j.critrevonc.2023.104223_bib78","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.canlet.2016.12.021","article-title":"Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy","volume":"388","author":"Bharti","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2023.104223_bib79","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.2217\/nnm-2018-0115","article-title":"Dual-targeting liposomes for enhanced anticancer effect in somatostatin receptor II-positive tumor model","volume":"13","author":"Li","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.critrevonc.2023.104223_bib80","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1021\/mp1000235","article-title":"A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models","volume":"7","author":"Zhang","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.critrevonc.2023.104223_bib81","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1021\/mp100380y","article-title":"Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma","volume":"8","author":"Iwase","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.critrevonc.2023.104223_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111272","article-title":"Electrostatically bound lanreotide peptide - gold nanoparticle conjugates for enhanced uptake in SSTR2-positive cancer cells","volume":"117","author":"Shelar","year":"2020","journal-title":"Mater. Sci. Eng. C."},{"key":"10.1016\/j.critrevonc.2023.104223_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25235672","article-title":"Recent progress in bioconjugation strategies for liposome-mediated drug delivery","volume":"25","author":"Almeida","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.critrevonc.2023.104223_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Guimar\u00e3es","year":"2021","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.critrevonc.2023.104223_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102513","article-title":"Epigenetic\u2010like Stimulation of Receptor Expression in SSTR2 Transfected HEK293 Cells as a New Therapeutic Strategy","volume":"14","author":"Kotzerke","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2023.104223_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.941832","article-title":"The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?","volume":"13","author":"Harris","year":"2022","journal-title":"Front Endocrinol. (Lausanne)"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823003116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823003116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:54:02Z","timestamp":1760903642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823003116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":86,"alternative-id":["S1040842823003116"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104223","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Somatostatin receptor2 (SSTR2) expression, prognostic implications, modifications and potential therapeutic strategies associates with head and neck squamous cell carcinomas","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104223"}}